# Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.

> **NCT02227433** · PHASE2 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 20 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT02227433
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-04
- **Primary completion:** 2018-04-03
- **Final completion:** 2020-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227433, "Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02227433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*